CMT2
CMT2 is the traditional label for axonal CMT, with motor nerve conduction velocities above about 45 m/s. Many different genes cause it. More in the glossary
-

·
On Deck: CMT Genes That Haven’t Been Rated Yet
A new report links AKAP6 to an axonal neuropathy in one family. Here’s why it isn’t in the Open CMT Gene Table yet, what the new candidate list holds, and how many CMT genes there might be.
-

·
What Happened to CMT2A1? KIF1B and the Disputed Rating
In October 2026 ClinGen’s Charcot-Marie-Tooth expert panel rated the KIF1B–CMT2A1 link “Disputed.” Here’s how that label arose, what the panel found, and how to interpret older references to the gene and disease variant.
-

·
CMT and Nutrition: What the Evidence Says
What the research says about diet, weight and CMT, why the supplements tested in CMT failed, which ones can hurt nerves, and the rare neuropathies where diet really is the treatment.
-

·
One Patient, One Drug—and a Possible Voucher
A drug made for a single patient is one of the most hopeful ideas in rare disease medicine. Drug companies hope to profit from them, if public funding and exclusive rights defray the costs of developing these drugs. People with rare diseases hope for a cure or better health outcomes. Can both interests align?
-

·
Plain-Language Research Summary: A Blood Test for Nerve-Fibre Loss in CMT
A 2025 study found the nerve-damage protein NfL more than twice as high in the blood of people with CMT, and loosely linked to severity. What it shows, what it can’t, and how it fits with earlier studies.
-

·
Name Games: Why CMT Type Names Are a Mess, and How to Find Reliable Information
CMT’s type names grew out of nerve tests and a run of lettered genes. They no longer line up. Here is how the naming got this messy, where it is heading, and which sources to trust.
-

·
Differential Diagnosis with Dr. ChatGPT in the House
In a matter of seconds, ChatGPT reviewed and confirmed the findings of three neurologists and a genetic counselor that took me six years to gather. It also suggested a new diagnostic path that was only vaguely hinted at by the human diagnosticians.
-

·
The “First Treatable CMT Disease” is Neither CMT Nor a Disease
CMT-related research may truly do away with CMT disease first by eliminating or updating how naming and classification works in neurological pathology.
-

·
The “first treatable” form of CMT?
I wrote this brief article on the way the SORD gene works (or fails to work) for the Hereditary Neuropathy Foundation. SORD mutations cause “the most common autosomal recessive form of CMT2 (CMT2A1), autosomal recessive intermediate CMT (CMTRIA), and the overlapping category of distal hereditary motor neuropathy (dHMN).”
-

·
All types of CMT are “Axonal”
CMT1 types have commonly been referred to as “demyelinating” and CMT2 as “axonal,” which gives the impression the nature of the nerve damage between the two is fundamentally different.
-

·
The Problem With Writing About CMT
I’ve been increasingly irritated lately by US-based CMT-related non-profit organizations that seem to compete with each other for donations — supposedly they drive research for “treatments and cures.” How well they actually do this relative to the padding of their own budgets is a good question I might take up down the line, but you…
-

·
CMT Blogs of Note
A refreshed directory of independent CMT, neuromuscular, chronic-pain, and disability-justice blogs and newsletters, checked October 2026.
-

·
A New Genetic Cause of a Previously Unknown Subtype of CMT2
Published in Nature Genetics last month, the INC group’s findings are a big deal, and there is a really cool story from the University of Miami’s Miller School of Medicine about how the research team came together.
-

·
New Study of Genetic Causes of CMT Needs Participants
The Rare Diseases Network is looking for participants in a new study looking for unknown causes of the most common types of CMT.
-

·
Genetic Cause of CMT2 Discovered?
A 2020 study linked JAG1 mutations to axonal CMT2 in two families. Updated in 2026: JAG1-related CMT now has its own OMIM entry, CMT2HH.
-

·
CMT and Respiratory Dysfunction
Science is starting to confirm very wide ranging effects to the nerve damage CMT does, often slowly and over time so it may not be very noticeable for many years.
-

·
New Genetic Diagnostics for CMT
Current best practice in genetic diagnosis of CMT starts with PMP22 testing. How genetic testing, nerve conduction studies, and EMG lead to a diagnosis.
-

·
Respiratory Problems and CMT
Earlier in life, relatively healthy people with CMT can overlook signs of compromised respiratory function which will start to cause more and more problems for them later.
-

·
Sleep Apnea and CMT
Studies show CMT tends to come with Disturbed Sleep, Depression, and Reduced Quality of Life. 😞 This post summarizes the scientific research I’ve absorbed on the subject of CMT and sleep apnea. It’s definitely accurate relative to my own experience in the past year or so.
-

·
The State of Research for Cures (2019)
The US-based CMTA (Charcot Marie Tooth Association) has a 12-year-old program called the Strategy to Accelerate Research (STAR) that is actively pursuing the causes and possible cures for CMT. STAR will cover nearly all CMT Type 1s and 2s, including types with as yet unidentified genetic causes.
